FIGURE 3.

Emerging genomic aberrations potentially contributed to gastric cancer's (GC) resistance to HER2‐targeted therapy. (A) The distribution of novel gene alterations emerged in 12 patients and their correlation with HER2‐targeted regimens. (B) The biological processes and pathways involved with the emerging genomic aberrations were enriched. (C) The real‐time frequency of primary copy number variations (CNVs), primary mutations, three novel ERBB2 point mutations, and maximum variant allele frequency changed along with the treatments in case 35. PTX, paclitaxel